课题基金 / 基金详情

DOXORUBICIN CARDIOTOXICITY IN PATIENTS W/ BREAST CANCER IS PREVENTED BY ICRF 187

DOXORUBICIN CARDIOTOXICITY IN PATIENTS W/ BREAST CANCER IS PREVENTED BY ICRF 187
ICRF 187 可预防乳腺癌患者的阿霉素心脏毒性
批准号：
3843452
负责人：
V J FERRANS
金额：
$0.0万
依托单位：
NATIONAL HEART, LUNG, AND BLOOD INSTITUTE
依托单位国家：
美国
项目类别：
财政年份：
--
资助国家：
美国
项目状态：
未结题
起止时间：
至
来源：
https://reporter.nih.gov/project-details/3843452
关键词：
biopsy cardiotoxin cardiovascular disorder prevention combination cancer therapy cyclophosphamide doxorubicin drug adverse effect female fluorouracil human subject human therapy evaluation myocardium myocardium disorder neoplasm /cancer chemotherapy neoplasm /cancer pharmacology

项目摘要

项目成果

V J FERRANS的其他基金

相似基金

相关文献

中文摘要
翻译
临床和心肌活检研究评估了这种保护作用。 ICRF 187在预防阿霉素慢性中毒中的作用 150例乳腺癌化疗患者的心肌病分析 阿霉素、环磷酰胺和5-氟尿嘧啶，加或不加ICRF 187.研究表明，ICRF对阿霉素具有保护作用。 乳腺癌女性患者在不改变心脏功能的情况下发生心脏毒性 该方案的抗肿瘤疗效或明显增加其毒性。 接受ICRF 187的妇女能够接受更多的周期和更高的 阿霉素的累积剂量与相当少的心脏毒性。
英文摘要
Clinical and myocardial biopsy studies were made to evaluate the protective role of ICRF 187 in the prevention of doxorubicin-induced chronic cardiomyopathy in 150 patients with breast cancer who received chemotherapy with doxorubicin, cyclophosphamide and 5-fluorouracil, with or without ICRF 187. The study showed that ICRF provides protection against doxorubicin- induced cardiac toxicity in women with breast cancer without altering the antitumor efficacy of the regimen or adding significantly to its toxicity. Women receiving ICRF 187 were able to receive more cycles and higher cumulative doses of doxorubicin with considerably less cardiac toxicity.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
STUDIES OF THE MORPHOLOGY OF THE BIOPROSTHETIC HEART VALVES
SURGICAL PATHOLOGY OF THE CARDIOVASCULAR SYSTEM
ULTRASTRUCTURE AND FUNCTION OF THE MYOCARDIUM--AN OVERVIEW
INTRALUMINAL FIBROSIS IN FIBROTIC LUNG DISORDERS
海外基金